Grantopen🌐 United StatesPAR-25-226
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
National Institutes of Health
Details?
- Posted
- Nov 22, 2024
- Response deadline
- Nov 19, 2026, 12:00 AM UTC (130d)
- Type
- Grant
- Category
- 93.242
- Status
- open
- Buyer
- National Institutes of Health
- Department
- HHS-NIH11
- Jurisdiction
- United States
- Reference #
- PAR-25-226
- Doc Type
- synopsis
- Opp Status
- posted
Finding similar opportunities…
This listing is a summary from United States's open procurement data. We ingest every field the feed publishes; the full solicitation documents are on the source portal.